Abstract: Objective To study the efficacy and safety of Apatinib in the treatment of advanced refractory tri-negative breast cancer. Method 22 patients with advanced tri-negative breast cancer treated with Apatinib from January 1,2017 to December 30,2018 in the affiliated hospital of Xuzhou University were retrospectively observed, and the medical history (symptoms and signs),laboratory and imaging examination results, short-term efficacy, adverse reactions and other contents were analyzed. Results Among the 22 patients who could evaluate the curative effect of the lesion,0 were in complete remission,5 were in partial remission,14 were in stable condition,3 were in disease progression, the objective remission rate was 22.73%,and the disease control rate was 86.36%.Adverse reactions are mainly proteinuria,hypertension,hand and foot syndrome. Mean progression-free survival was 5.3 months and median progression-free survival was 4.1 months. Conclusion Patients with advanced refractory tri-negative breast cancer (TNBC) have good short-term efficacy and controllable adverse reactions after the periodic treatment with Apatinib